DONOR LEUKOCYTE INFUSIONS FOR CHRONIC MYELOID LEUKEMIA IN RELAPSE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION

To the Editor:
Allogeneic bone marrow transplantation (BMT) is the only curative therapy for chronic myeloid leukemia (CML), but relapse occurs in approximately 10% of patients transplanted in chronic phase with non T-cell-depleted marrow.'" The risk of relapse is substantially greater if T-cell depletion of donor marrow is used as prophylaxis against graft-versus-host disease (GVHD), when relapse rates of 50% or more have been observed.' Management of patients in relapse after BMT is difficult: conventional chemotherapy with hydroxyurea or busulfan offers little prospect of prolonging survival, and cytogenetic remissions after a-interferon (IFN) are rare! Second bone marrow transplants carry a high morbidity and mortality? We report here our experience of treating two patients in cytogenetic relapse after allogeneic BMT with infusions of viable donor bufTy coat without additional chemotherapy.
Unique patient number (UPN) 197 is a 32-year-old woman who received a T-lymphocytedepleted BMT in June 1989 from a phenotypically HLA-identical unrelated male donor, while in the accelerated phase of Ph-positive CML. She developed grade I1 acute skin GVHD, which responded rapidly to oral prednisolone. A routine follow-up marrow 3 months post-BMT showed 19 normal donor metaphases and a solitary 46,XX,Ph-positive metaphase out of 20 examined. Over the subsequent 11 months the proportion of Ph-positive female metaphases in the marrow gradually increased (Table 1) . During this period she developed mild chronic oral GVHD, necessitating treatment with prednisolone and cyclosporin A (CSA). In June 1990 immunosuppressive therapy was discontinued. In August 1990, a marrow aspirate showed 21 of 21 46,XX,Ph-positive metaphases, although there was no evidence of hematologic relapse. Karyotypic studies of her peripheral blood lymphocytes suggested the presence of a chimeric lymphoid population (Table 2) .
In August 1990 she received two infusions of fresh buEy coat, containing 2.7 x l@/kg nucleated cells, collected by leukapheresis from the original marrow donor. She received no prior conditioning or GVHD prophylaxis. One week after the second infusion she developed grade I11 acute skin GVHD, which was treated with oral prednisolone and CSA: PUVA therapy was introduced 1 month later because of poor response. Her skin gradually improved over the next few weeks, and in November 1990, 3 months post-bufTy coat infusion, a bone marrow aspirate showed 30 of 30 46,XY normal metaphases (Table 1) . Repeat studies of her peripheral blood lymphocytes at this stage showed 100% donor cells (Table 2) . Leukemia-specific BCR/ABL mRNA was detectable in peripheral blood at this stage using the polymerase chain reaction (PCR) according to the method of Hughes et al. ' In December 1990 she developed extensive chronic skin and oral GVHD. There was little response to alternate day steroids and CSA, and she lost considerable weight. Thalidomide was commenced with modest improvement. In May 1991 she remained in complete hematologic and cytogenetic remission. BCR/ABL tran- Because of her previous GVHD, she was given CSA and shortcourse methotrexate (MTX) as GVHD prophylaxis. She remained well, but 2 months post-infusion her marrow remained substantially Ph-positive (Table l) , and therefore CSA was stopped. A further marrow examination in March 1991 showed eight of eight 46,XY normal metaphases. Shortly after this she developed mild oral and skin GVHD, which responded rapidly to oral steroids. In July 1991 she remained in complete hematologic and cytogenetic remission. PCR studies, performed on peripheral blood, were positive for CML transcripts in February and May 1991, but were negative at time of most recent studies in August 1991.
The remissions attained by these two patients after buffy coat infusions provide further clinical evidence for the existence of a specific graft-versus-leukemia (GVL) effect after allogeneic BMT.8 It seems likely that an important component of this effect is mediated by donor T lymphocytes.',' The antileukemic effect of GVHD is well established: GVHD is associated with decreased relapse rates after BMT for CML.',c'o Removal of donor T cells reduces the incidence and severity of GVHD, but greatly increases the risk of relapse."' However, patients who develop GVHD despite T-cell depletion still have an increased incidence of relapse: as is the case in our two patients. This suggests that T-cell subsets mediating GVL and GVHD may be separable. This is best illustrated by UPN 116, who relapsed despite extensive GVHD after BMT; she reverted to cytogenetic remission following buffy coat infusion, but only developed minimal GVHD.
Infusions of donor buffy coat have previously been used in leukemia therapy. Sullivan et all' gave donor buffy coat to patients with advanced acute leukemia shortly after BMT in an attempt to reduce relapse risk; however, recipients of this therapy showed similar relapse rates to controls, and had more acute GVHD and reduced survival. More recently Kolb et all2 has reported three patients in relapse after BMT for CML, treated with IFN and donor leukocyte infusions. All three attained hematologic and cytogenetic remissions: two patients developed GVHD. These cases differ in several respects from our own: the patients were all in hematologic relapse, and had undergone non T-cell-depleted transplants. None had developed GVHD at time of BMT. All received IFN concurrent with the donor leukocytes. In addition, we have obtained PCR data on both of our patients: although both remained PCR positive during the first 6 months after buffy coat infusion, UPN 197 was PCR negative at 10 and 12 months, and UPN 116 became PCR negative at 9 months. Although the prognostic significance of these findings is uncertain, the pattern of results is similar to that observed after non T-cell-depleted allogeneic BMT,' and suggests that the risk of further relapse for these two patients is similarly low. We believe that donor buffy coat infusions merit consideration in patients who relapse after BMT for CML; however, the development of extensive GVHD in one of our patients indicates that this therapy requires further evaluation. For personal use only. on January 15, 2018. by guest www.bloodjournal.org From
